Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge

Vaccine

Volumn 29, Issue 28, 2011, Pages 4638-4645

  Mustafa, Waleed ^a,b   Al Saleem, Fetweh H ^a   Nasser, Zidoon ^a   Olson, Rebecca M ^a   Mattis, Jeffrey A ^b   Simpson, Lance L ^a   Schnell, Matthias J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MOLECULAR TARGETING TECHNOLOGIES INC   (United States)

Author keywords

Botulinum neurotoxin; HC50; Rabies virus; Rhaboviral vector; Vaccine

Indexed keywords

BOTULINUM TOXIN A; CHIMERIC PROTEIN; HEAVY CHAIN CARBOXYTERMINAL HALF; IMMUNOGLOBULIN G ANTIBODY; RABIES VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; GENETIC PROCEDURES; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABIES; RABIES VIRUS; VIRUS PARTICLE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; BACTERIAL VACCINES; BOTULINUM TOXINS, TYPE A; BOTULISM; FEMALE; GENETIC VECTORS; GLYCOPROTEINS; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; RABIES VIRUS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRION;

EID: 79958147874     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.045     Document Type: Article

References (51)

1. Hatheway C.L. Botulism: the present status of the disease. Curr Top Microbiol Immunol 1995, 195:55-75.
2. Shukla H.D., Sharma S.K. Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol 2005, 31(1):11-18.
3. Turton K., Chaddock J.A., Acharya K.R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 2002, 27(November (11)):552-558.
4. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285(February (8)):1059-1070.
5. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000, 80(April (2)):717-766.
6. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004, 44:167-193.
7. Haupt W. Rabies - risk of exposure and current trends in prevention of human cases. Vaccine 1999, 17(March (13-14)):1742-1749.
8. Plotkin S.A. Rabies vaccine prepared in human cell cultures: progress and perspectives. Rev Infect Dis 1980, 2(May-Jun (3)):433-448.
9. Thraenhart O., Kreuzfelder E., Hillebrandt M., Marcus I., Ramakrishnan K., Fu Z.F., et al. Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man. Clin Immunol Immunopathol 1994, 71(June (3)):287-292.
10. McKenna P.M., McGettigan J.P., Pomerantz R.J., Dietzschold B., Schnell M.J. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr HIV Res 2003, 1(April (2)):229-237.
11. Schnell M.J., Foley H.D., Siler C.A., McGettigan J.P., Dietzschold B., Pomerantz R.J. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci USA 2000, 97(March (7)):3544-3549.
12. Siler C.A., McGettigan J.P., Dietzschold B., Herrine S.K., Dubuisson J., Pomerantz R.J., et al. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 2002, 292(January (1)):24-34.
13. Smith M.E., Koser M., Xiao S., Siler C., McGettigan J.P., Calkins C., et al. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology 2006, 353(September (2)):344-356.
14. Fehr T., Bachmann M.F., Bucher E., Kalinke U., Di Padova F.E., Lang A.B., et al. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 1997, 185(May (10)):1785-1792.
15. Jegerlehner A., Storni T., Lipowsky G., Schmid M., Pumpens P., Bachmann M.F. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol 2002, 32(November (11)):3305-3314.
16. Hooper D.C., Pierard I., Modelska A., Otvos L., Fu Z.F., Koprowski H., et al. Rabies ribonucleocapsid as an oral immunogen and immunological enhancer. Proc Natl Acad Sci USA 1994, 91(November (23)):10908-10912.
17. Torii Y., Tokumaru Y., Kawaguchi S., Izumi N., Maruyama S., Mukamoto M., et al. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Vaccine 2002, 20(June (19-20)):2556-2561.
18. Fiock M.A., Devine L.F., Gearinger N.F., Duff J.T., Wright G.G., Kadull P.J. Studies on immunity to toxins of Clostridium botulinum. VIII. Immunological response of man to purified bivalent AB botulinum toxoid. J Immunol 1962, 88(March):277-283.
19. Fiock M.A., Cardella M.A., Gearinger N.F. Studies on immunity to toxins of Clostridium Botulinum, Ix. Immunologic response of man to purified pentavalent Abcde Botulinum toxiod. J Immunol 1963, 90(May):697-702.
20. Jones R.G., Liu Y., Rigsby P., Sesardic D. An improved method for development of toxoid vaccines and antitoxins. J Immunol Methods 2008, 337(August (1)):42-48.
21. Keller J.E. Characterization of new formalin-detoxified botulinum neurotoxin toxoids. Clin Vaccine Immunol 2008, 15(September (9)):1374-1379.
22. Baldwin M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., et al. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun 2005, 73(October (10)):6998-7005.
23. Baldwin M.R., Tepp W.H., Przedpelski A., Pier C.L., Bradshaw M., Johnson E.A., et al. Subunit vaccine against the seven serotypes of botulism. Infect Immun 2008, 76(March (3)):1314-1318.
24. Yu Y.Z., Li N., Zhu H.Q., Wang R.L., Du Y., Wang S., et al. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 2009, 27(May (21)):2816-2822.
25. Bennett A.M., Perkins S.D., Holley J.L. DNA vaccination protects against botulinum neurotoxin type F. Vaccine 2003, 21(July (23)):3110-3117.
26. Jathoul A.P., Holley J.L., Garmory H.S. Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters. Vaccine 2004, 22(September (29-30)):3942-3946.
27. Lee J.S., Pushko P., Parker M.D., Dertzbaugh M.T., Smith L.A., Smith J.F. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun 2001, 69(September (9)):5709-5715.
28. Lee J.S., Groebner J.L., Hadjipanayis A.G., Negley D.L., Schmaljohn A.L., Welkos S.L., et al. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 2006, 24(November (47-48)):6886-6892.
29. Yu Y.Z., Zhang S.M., Sun Z.W., Wang S., Yu W.Y. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 2007, 25(December (52)):8843-8850.
30. Zeng M., Xu Q., Elias M., Pichichero M.E., Simpson L.L., Smith L.A. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 2007, 25(October (43)):7540-7548.
31. Xu Q., Pichichero M.E., Simpson L.L., Elias M., Smith L.A., Zeng M. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther 2009, 16(March (3)):367-375.
32. Foynes S., Holley J.L., Garmory H.S., Titball R.W., Fairweather N.F. Vaccination against type F botulinum toxin using attenuated Salmonella enterica var Typhimurium strains expressing the BoNT/F H(C) fragment. Vaccine 2003, 21(March (11-12)):1052-1059.
33. Maksymowych A.B., Simpson L.L. Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells. J Pharmacol Exp Ther 2004, 310(August (2)):633-641.
34. McGettigan J.P., Sarma S., Orenstein J.M., Pomerantz R.J., Schnell M.J. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol 2001, 75(September (18)):8724-8732.
35. Mebatsion T. Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein. J Virol 2001, 75(December (23)):11496-11502.
36. Foley H.D., McGettigan J.P., Siler C.A., Dietzschold B., Schnell M.J. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc Natl Acad Sci USA 2000, 97(December (26)):14680-14685.
37. DasGupta B.R., Sathyamoorthy V. Purification and amino acid composition of type A botulinum neurotoxin. Toxicon 1984, 22(3):415-424.
38. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther 1982, 19(2):165-194.
39. Simpson L.L., Schmidt J.J., Middlebrook J.L. Isolation and characterization of the Botulinum neurotoxins. Methods Enzymol 1988, 165:76-85.
40. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227(August (5259)):680-685.
41. Ravichandran E., Al-Saleem F.H., Ancharski D.M., Elias M.D., Singh A.K., Shamim M., et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 2007, 75(June (6)):3043-3054.
42. Byrne M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82(September-October (9-10)):955-966.
43. Byrne M.P., Smith T.J., Montgomery V.A., Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 1998, 66(October (10)):4817-4822.
44. Clayton M.A., Clayton J.M., Brown D.R., Middlebrook J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 1995, 63(July (7)):2738-2742.
45. Zinkernagel R.M., On natural, artificial vaccinations. Annu Rev Immunol 2003, 21:515-546.
46. Baumgarth N. A two-phase model of B-cell activation. Immunol Rev 2000, 176(August):171-180.
47. LaPenotiere H.F., Clayton M.A., Middlebrook J.L. Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Toxicon 1995, 33(October (10)):1383-1386.
48. Wunner W.H. The chemical composition and molecular structure of rabies viruses. The natural history of rabies 1991, 31-67. Elsevier/Academic Press, Amsterdam, Boston. G.M. Baer (Ed.).
49. Atassi M.Z., Oshima M. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol 1999, 19(3):219-260.
50. Chen F., Kuziemko G.M., Amersdorfer P., Wong C., Marks J.D., Stevens R.C. Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect Immun 1997, 65(May (5)):1626-1630.
51. Oshima M., Hayakari M., Middlebrook J.L., Atassi M.Z. Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855-1296) of the toxin. Mol Immunol 1997, 34(October (14)):1031-1040.